Table 3.
Treatment outcomes on recurrence with chemotherapy for recurrent or metastatic disease.
| Median survival | p value | HR | 95% CI | |
|---|---|---|---|---|
| OS by pathology on recurrence | ||||
| High-grade sarcomatous component only | 17.6 mo | |||
| Similar to initial pathology | 33.5 mo | 0.035 | 0.47 | 0.23–0.96 |
| 1st line chemotherapy | ||||
| OS | ||||
| All patients | 16.6 mo | — | ||
| Doxorubicin-based regimen | 14.9 mo | — | ||
| Doxorubicin/ifosfamide | 22.5 mo | ref | ||
| Other doxorubicin-based regimens | 13.1 mo | 0.18 | 2.18 | 0.69–6.88 |
| Gemcitabine/docetaxel | 24.9 mo | 0.99 | 0.99 | 0.30–3.38 |
| Platinum-based regimen | 24.3 mo | 0.49 | 0.60 | 0.14–2.53 |
| PFS | ||||
| All patients | 7.0 mo | — | ||
| Doxorubicin-based regimen | 8.5 mo | — | ||
| Doxorubicin/ifosfamide | 15.4 mo | ref | ||
| Other doxorubicin-based regimens | 6.5 mo | 0.083 | 2.65 | 0.88–7.98 |
| Gemcitabine/docetaxel | 5.0 mo | 0.27 | 1.87 | 0.62–5.63 |
| Platinum-based regimen | 5.7 mo | 0.06 | 3.08 | 0.95–9.93 |
| 1st line chemotherapy additional treatments | ||||
| OS | ||||
| Surgery | 21.6 mo | |||
| No surgery | 11.9 mo | 0.12 | 1.36 | 0.73–2.53 |
| PFS | ||||
| Surgery | 12.0 mo | |||
| No surgery | 3.6 mo | 0.02 | 2.04 | 1.10–3.77 |
| OS by hormonal therapy for patients with recurrence | ||||
| Received hormonal therapy | 34.7 mo | |||
| No hormonal therapy | 17.6 mo | 0.15 | 1.58 | 0.85–2.95 |
| OS therapy for 1st recurrence | 21.8 mo | |||
| Surgery | 26.3 mo | |||
| No surgery | 15.1 mo | 0.54 | 1.21 | 0.66–2.24 |
| Radiation | 16.5 mo | |||
| No radiation | 23.4 mo | 0.58 | 0.83 | 0.42–1.63 |
| Chemotherapy | 18.6 mo | |||
| No chemotherapy | 27.6 mo | 0.58 | 0.85 | 0.47–1.53 |
| Chemotherapy + surgery | 23.4 mo | |||
| No chemotherapy + surgery | 16.5 mo | 0.97 | 1.01 | 0.55–1.85 |
OS, overall survival; PFS, progression-free survival; TTP, time to progression.